Artiva Biotherapeutics (ARTV) Cash from Investing Activities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Cash from Investing Activities data on file, last reported at $15.3 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 53.61% year-over-year to $15.3 million in Q1 2026; TTM through Mar 2026 was $68.8 million, a 157.17% increase from a year earlier, with the FY2025 full-year figure at $63.4 million, up 152.64% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $15.3 million, down from $16.0 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for ARTV reached as high as $21.1 million in Q2 2025 and fell as low as -$130.6 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$4.1 million across 4 years, with a median of $9.8 million in 2024.
• Across the five-year window, Cash from Investing Activities plunged 26396.55% in 2024 and soared 1760.46% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$2.7 million in 2023, then jumped by 63.79% to -$966000.0 in 2024, then surged by 1760.46% to $16.0 million in 2025, then declined by 4.51% to $15.3 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $15.3 million in Q1 2026, $16.0 million in Q4 2025, and $16.3 million in Q3 2025.